Conversion to Monotherapy Study With Keppra XR for Partial Seizures

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Male or female subjects 12 to 75 years of age.

• Subjects must have inadequately controlled partial onset epilepsy.

• Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s)

Exclusion Criteria:

• A history of status epilepticus in the 6 months preceding randomization.

• Significant medical, psychiatric or neurological illness.

• Intake of benzodiazepines on more than an occasional basis

• History of previous treatment with levetiracetam or sensitivity to levetiracetam.